Literature DB >> 27635042

Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?

Katherine Eason1, Anguraj Sadanandam2.   

Abstract

Tumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-specific genomic or transcriptomic profiles. Subtyping can lead to biomarker identification for personalized diagnosis and therapy, but stratification alone does not explain the origins of tumor heterogeneity. Heterogeneity has traditionally been thought to arise from distinct mutations/aberrations in "driver" oncogenes. However, certain subtypes appear to be the result of adaptation to the disrupted microenvironment caused by abnormal tumor vasculature triggering metabolic switches. Moreover, heterogeneity persists despite the predominance of single oncogenic driver mutations, perhaps due to second metabolic or genetic "hits." In certain cancer types, existing subtypes have metabolic and transcriptomic phenotypes that are reminiscent of normal differentiated cells, whereas others reflect the phenotypes of stem or mesenchymal cells. The cell-of-origin may, therefore, play a role in tumor heterogeneity. In this review, we focus on how cancer cell-specific heterogeneity is driven by different genetic or metabolic factors alone or in combination using specific cancers to illustrate these concepts. Cancer Res; 76(18); 5195-200. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27635042     DOI: 10.1158/0008-5472.CAN-16-0141

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Molecular subtypes in cancers of the gastrointestinal tract.

Authors:  Maarten F Bijlsma; Anguraj Sadanandam; Patrick Tan; Louis Vermeulen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

2.  TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.

Authors:  Hitoshi Itoh; Tsuyoshi Kadomatsu; Hironori Tanoue; Masaki Yugami; Keishi Miyata; Motoyoshi Endo; Jun Morinaga; Eisuke Kobayashi; Takeshi Miyamoto; Ryoma Kurahashi; Kazutoyo Terada; Hiroshi Mizuta; Yuichi Oike
Journal:  Oncogene       Date:  2018-03-08       Impact factor: 9.867

Review 3.  Pancreatic cancer subtypes: a roadmap for precision medicine.

Authors:  Carolina Torres; Paul J Grippo
Journal:  Ann Med       Date:  2018-03-22       Impact factor: 4.709

4.  Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase.

Authors:  Jason R Cantor; Monther Abu-Remaileh; Naama Kanarek; Elizaveta Freinkman; Xin Gao; Abner Louissaint; Caroline A Lewis; David M Sabatini
Journal:  Cell       Date:  2017-04-06       Impact factor: 41.582

5.  Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer.

Authors:  Jia-Yue Zou; Yu-Jie Huang; Jun He; Zu-Xiong Tang; Lei Qin
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

Review 6.  VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation.

Authors:  Diana Fang; Eduardo N Maldonado
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 7.  VDAC-Tubulin, an Anti-Warburg Pro-Oxidant Switch.

Authors:  Eduardo N Maldonado
Journal:  Front Oncol       Date:  2017-01-23       Impact factor: 6.244

8.  Alterations in glycolytic/cholesterogenic gene expression in hepatocellular carcinoma.

Authors:  Jianwen Jiang; Qiuxian Zheng; Weiwei Zhu; Xinhua Chen; Haifeng Lu; Deying Chen; Hua Zhang; Min Shao; Lin Zhou; Shusen Zheng
Journal:  Aging (Albany NY)       Date:  2020-06-01       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.